Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of one the following:~  * Acute myelogenous leukemia in CR1, ER1, CR2, ER2, CR3~ * Acute lymphocytic leukemia in CR1, ER1, CR2, ER2, CR3~ * Non-Hodgkin's lymphoma~ * Hodgkin's lymphoma~ * Multiple myeloma with no more than 12 months of prior alkylator based chemotherapy~ * Myelodysplastic syndrome (MDS)~ * Acute leukemia arising out of MDS~ * Primary resistant acute leukemia~ * Chronic myelomonocytic leukemia~ * Aplastic anemia (40 years of age and over)~ * Solid tumor malignancy (germ cell, sarcoma, breast, etc.)~ * Genetic disorders or inborn errors of metabolism as defined by preparative regimen protocol~ * Chronic myelogenous leukemia~* Must meet all inclusion criteria specified by the respective preparative regimen protocol~* No aplastic anemia under 40 years of age or myelofibrosis~PATIENT CHARACTERISTICS:~Age:~* 0.5 to 65~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior red blood cell or platelet transfusions from a sibling donor~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).